TNF and Parkinson disease: Furthermore, in a PD mouse model, oral administration of Rg1 significantly attenuates behavior defects, loss of dopamine neurons, and abnormal ultrastructure changes and regulates activation of astrocytes and microglia by decreasing release of cytokines such as TNF-α and IL-1β in substantia nigra [104].